U.K.'s CMA Clears Sony's Acquisition Of AWAL

The Competition and Markets Authority in the UK said it has cleared Sony's acquisition of AWAL, an 'artist and label' or A&L services provider, following an in-depth merger inquiry.

AWAL is an emerging music distributor offering an alternative to traditional music deals by providing both A&L services and a 'DIY platform' that allows artists to upload their own music for distribution.

Margot Daly, Chair of the independent CMA Inquiry Group, said, "Having carefully assessed the merger we found that it is not likely to affect competition in a way that will reduce the choice or quality of recorded music available or increase prices."

In February 2022, the CMA provisionally cleared Sony's acquisition of AWAL.

In February 2021, Sony Music Entertainment agreed to buy 100% of the shares and related assets of certain Kobalt Music Group subsidiaries in order to obtain AWAL for $430 million.

In September 2021, the CMA referred Sony Music's acquisition of AWAL for a Phase 2 investigation.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT